Clinical study of tazobactam/piperacillin

We evaluated the clinical efficacy and safety of tazobactam/piperacillin (TAZ/PIPC), a drug combining a β-lactamase inhibitor and penicillin. TAZ/PIPC was administrated to 11 patients with infections. The patients received the drug intravenously for 4 to 14 days at a dose of 1.25-5.0 g/day. Clinical...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 42; no. Supplement2; pp. 710 - 712
Main Authors Wada, Kouichi, Sega, Hiroyuki, Yoshikawa, Hiroko, Tsukada, Hiroki, Arakawa, Masaaki
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1994
Subjects
Tazobactam/Piperacillin
Online AccessGet full text

Cover

More Information
Summary:We evaluated the clinical efficacy and safety of tazobactam/piperacillin (TAZ/PIPC), a drug combining a β-lactamase inhibitor and penicillin. TAZ/PIPC was administrated to 11 patients with infections. The patients received the drug intravenously for 4 to 14 days at a dose of 1.25-5.0 g/day. Clinical effects were good in 10 and unknown in 1. No side effects were noticed. As abnormal laboratory findings, elevations of GOT and GPT were observed in two cases.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.42.Supplement2_710